ORIC Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs
“ORIC Pharmaceuticals is positioning two lead candidates for major late-stage advancement in 2026, with rinzimetostat (formerly ORIC-944) set to enter its first global Phase 3 trial in metastatic castration-resistant prostate cancer in the first half of the year, and enozertinib (ORIC-114) advancing toward registrational trials in first-line non-small cell lung cancer. The company anticipates multiple … Read more